Overall, these data suggest a scenario in which the efficacy of IFN-β in the treatment of MS rests on wide immunomodulatory effects resulting, at least in part, from its antiviral properties (Figure 1). The gene discussed is IFNB1; the disease is myeloid sarcoma.